Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology…
FAIL · Does not pass the screen
0.95 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 18:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price0.95 USD at the 4 Nov 2026 close
Fair valueUnder review: its inputs are 14 days old; there is no analyst estimate to cross-check it.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price0.95 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-10-25Read Markup0.97-2.1% to today Markdown gives way to Markup first Markup read since October
2026-10-16Read Markdown0.97-2.1% to today ✓Markup gives way to Markdown after a 288% rise in 7 weeks
2026-08-27Read Markup0.25+280.0% to today ✓Accumulation gives way to Markup with volume flow in agreement
2026-07-02Read Accumulation0.25+280.0% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Eagle Pharmaceuticals, Inc. holds its Markup at $0.95. The statistical read favours the sellers, held for 7 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 7 days
Price at the screen
$0.95
Valuation
5.63 trailing · 0.26 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.66
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2,202.66%
Below 33%
Interest-bearing debt is 2,202.7% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
466.77%
Below 33%
Interest-bearing cash and securities are 466.8% of assets, above the one-third limit.
Fail
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.09%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Eagle Pharmaceuticals,'s business is in a permissible area, but its interest-bearing debt is about 2203% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when EGRX's ethical verdict changes
Today EGRX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Its inputs are 14 days old; there is no analyst estimate to cross-check it. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
EGRX trades on PNK. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$0.95-2.1%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-10-25Markup · changed$0.97+0.0%Entry 8
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading oversold. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-10-16Markdown · changed$0.97+7.8%Entry 7
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 7.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-10-02Markup$0.90+260.0%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 260.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 14%. Since the last review it its composite score eased.
2026-08-27Markup · changed$0.25+0.0%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-07-27Accumulation$0.25+0.0%Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-07-18Accumulation$0.25+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 73%. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-07-03Accumulation$0.25+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$0.25Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$0.38
+57.9%
·
$1,579
+57.9%
2 months
$0.34
+76.0%
·
$1,760
+76.0%
3 months
$0.34
+76.0%
·
$1,760
+76.0%
6 months
$0.51
+17.7%
·
$1,177
+17.7%
1 year
$2.25
-73.3%
·
$267
-73.3%
2 years
$3.71
-83.8%
·
$162
-83.8%
3 years
$18.88
-96.8%
·
$32
-96.8%
5 years
$40.85
-98.5%
·
$15
-98.5%
Historical returns from market close data. Past performance does not guarantee future results.
The Ledger's Promise
This entry now belongs to the ledger. Whatever EGRX does next, these words stay.
Eagle Pharmaceuticals, Inc. · EGRX · Markup · $0.95
Recorded 2026-11-04 · before the outcome · scored mechanically